NCT04152291View on ClinicalTrials.gov

The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism

NACompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
AtherosclerosisLow-density Lipoproteins Aggregation SusceptibilityLow-density Lipoprotein Lipid CompositionCardiovascular Diseases
Interventions
DIETARY_SUPPLEMENT

Ethyl-Eicosapentaenoic Acid (E-EPA)

3,9 grams of E-EPA (Icosapent ethyl) is added to participants' normal diet.

Trial Locations (1)

Unknown

Wihuri Research Institute, Helsinki

All Listed Sponsors
collaborator

University of Helsinki

OTHER

lead

Wihuri Research Institute

OTHER

NCT04152291 - The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism | Biotech Hunter | Biotech Hunter